Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
在市场风起云涌和不确定时期，即使市场处于历史最高点，许多投资者也会转向股息率高的股票。这些公司通常具有高自由现金流并以高股息派息回报股东。
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.
Benzinga的读者可以查看我们的分析师股票评级页面，查看最新的分析师对他们最喜爱的股票的看法。交易员可以浏览Benzinga的广泛分析师评级数据库，包括按分析师准确性排序。
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
以下是医疗保健板块三只高收益股票最准确的分析师评级。
Gilead Sciences, Inc. (NASDAQ:GILD)
吉利德科学股份有限公司（纳斯达克股票代码：GILD）
- Dividend Yield: 4.47%
- Baird analyst Brian Skorney maintained a Neutral rating with a price target of $80 on June 20. This analyst has an accuracy rate of 64%.
- RBC Capital analyst Brian Abrahams reiterated a Sector Perform rating with a price target of $74 on June 14. This analyst has an accuracy rate of 66%.
- Recent News: On June 26, Gilead Sciences Canada announced Phase 3 PURPOSE 1 Trial results.
- Benzinga Pro's real-time newsfeed alerted to latest GILD's news
- 股息收益率：4.47%
- 贝尔德分析师布赖恩·斯科尼（Brian Skorney）于6月20日维持了中立评级，目标价为80美元。该分析师的准确率为64%。
- RBC资本分析师布赖恩·亚伯拉罕斯（Brian Abrahams）于6月14日重申板块表现评级，目标价为74美元。该分析师的准确率为66%。
- 最近的资讯：6月26日，吉利德科学加拿大宣布了3期PURPOSE 1试验结果。
- Benzinga Pro的即时新闻提醒了最新的GILD资讯。
CVS Health Corporation (NYSE:CVS)
西维斯健康公司（纽约证券交易所股票代码：CVS）
- Dividend Yield: 4.56%
- JP Morgan analyst Lisa Gill maintained an Overweight rating and cut the price target from $101 to $86 on May 30. This analyst has an accuracy rate of 60%.
- Argus Research analyst Chris Graja maintained a Buy rating and slashed the price target from $100 to $80 on May 8. This analyst has an accuracy rate of 69%.
- Recent News: On May 1, CVS Health reported first-quarter sales of $88.4 billion, up 3.7% year over year. It missed the consensus of $89.21 billion.
- Benzinga Pro's charting tool helped identify the trend in CVS stock.
- 股息收益率：4.56%
- JP摩根分析师Lisa Gill于5月30日维持超配评级，将价格目标从101美元下调至86美元。该分析师的准确率为60%。
- 雅运股份研究分析师Chris Graja于5月8日维持买入评级，将价格目标从100美元下调至80美元。该分析师的准确率为69%。
- 最近的资讯：5月1日，西维斯健康报告了第一季度销售额为884亿美元，同比增长3.7%。它未能达到89.21亿美元的共识。
- Benzinga Pro的图表工具帮助识别了CVS股票的趋势。
Johnson & Johnson (NYSE:JNJ)
强生公司（纽交所股票代码：JNJ）
- Dividend Yield: 3.40%
- Cantor Fitzgerald analyst LouiseChenreiterated an Overweight rating with a price target of $215 on June 25. This analyst has an accuracy rate of 69%.
- B of A Securities analyst GeoffMeachammaintained a Neutral rating and cut the price target from $180 to $170 on April 17. This analyst has an accuracy rate of 62%.
- Recent News: On June 21, Johnson & Johnson announced that it has successfully completed the acquisition of Proteologix, Inc.
- Benzinga Pro's signals feature notified of a potential breakout in JNJ's shares.
- 股息收益率：3.40%
- 康泰纳仕分析师路易丝·陈（Louise Chen）于6月25日重申超配评级，目标价为215美元。该分析师的准确率为69%。
- B of A证券分析师GeoffMeacham于4月17日维持中立评级，将价格目标从180美元下调至170美元。该分析师的准确率为62%。
- 最近的资讯：6月21日，强生公司宣布已成功完成对Proteologix公司的收购。
- Benzinga Pro的信号功能通知了JNJ股票潜在的突破。
Read More: How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro
阅读更多：如何使用Benzinga Pro查找分红股票：扫描、分析和捕捉